

C1
medicinal product can be intended for immunization ex situ or in situ. The invention also relates to the use of said peptide compound for increasing, in culture medium, the tumor CTL population and/or inducing the secretion by said CTLs of cytotoxic factors, such as for example IL-2, IFN- γ or TNF, and/or for stimulating the immune defenses, in particular so as to increase the tumor CTL population and/or induce the secretion by said CTLs of cytotoxic factors, such as for example IL-2, IFN- γ or TNF.--

IN THE CLAIMS:

Amend the claims as follows:

C2 26
51
--7. (THREE TIMES AMENDED) A peptide compound comprising a sequence of at least 8 consecutive amino acids of a natural hsp70 sequence, the sequence having at least one [mutation or modification] with respect to, and having at least 80% homology with, the amino acids sequence comprised between amino acids 286 and 294 of natural hsp70, said peptide being able to induce a specific T-cell immune response.--

--8. (twice amended) The peptide compound as claimed in claim 7, wherein the amino acid sequence is selected from the group consisting of: SLFEGIDIY (SEQ ID No

1), SLFEGIDIYT (SEQ ID No 2), SLFEGIDLY, SLFEGIDVY, SLFEGIDAY and SLFEGIDGY.

--9. (TWICE AMENDED) The peptide compound as claimed in claim 7, wherein the amino acid sequence is selected from the group consisting of: SLFEGIDIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2).--

C₂
--10. (TWICE AMENDED) The peptide compound as claimed in claim 9, wherein the amino acid sequence is SEQ ID No. 1.--

mb
91
--11. (THREE TIMES AMENDED) The peptide compound as claimed in claim 7, further comprising at least one element selected from the group consisting of:

- a protective chemical group reacting with the NH₂ or COOH, or with both NH₂ and COOH, provided that this modification does not significantly lower the immunogenicity of the peptide,

- a ^{which is?} [chemical group] improving the effectiveness of a vaccine in vivo,

- lipids or fatty acids, covalently linked to the peptide fragments so as to form lipopeptides,

C2 mb 2/17
- a carrier protein possessing restriction sites and enabling intact peptide fragments to be conveyed to their sites of action in the body.--

C3 mb 2/17
--13. (THREE TIMES AMENDED) A vector for expressing the peptide compound as claimed in claim 7, comprising a DNA fragment encoding for said peptide compound, wherein the DNA fragment is fused to a promoter that is (strong and effective) in eukaryotic or in prokaryotic cells or in both eukaryotic and prokaryotic cells.--

C4 mb 2/17
--19. (TWICE AMENDED) A pharmaceutical composition (comprising) a peptide compound according to claim 7 and a pharmaceutically acceptable vehicle.--

C5 mb 2/17
--34. (TWICE AMENDED) A method for immunizing at a ^{what} (distance) from a tumor(s), comprising administering to a patient a medicinal product comprising a peptide compound comprising a sequence of at least 8 consecutive amino acids of a natural hsp70 sequence the sequence having at least one (mutation or modification) with respect to the natural hsp70 sequence, and wherein the peptide compound brings about a specific T-cell immune response.--

C5
mb
917

--35. (TWICE AMENDED) A method for immunizing by direct injection in a tumor(s) or at an immediate vicinity near a tumor(s), comprising administering to a patient a medicinal product comprising a sequence of at least 8 consecutive amino acids of a natural hsp70 sequence the sequence having at least one mutation or modification with respect to the natural hsp70 sequence, and wherein the peptide compound brings about a specific T-cell immune response.--

Add the following new claims:

C6
mb
917

--64. A pharmaceutical composition comprising a peptide compound according to claim 8 and a pharmaceutically acceptable vehicle.--

C6

--65. A pharmaceutical composition comprising a peptide compound according to claim 9 and a pharmaceutically acceptable vehicle.--

Please charge the fee of \$36 for the two extra claims added herewith, to our Deposit Account No. 25-0120.